- Stocks
- Pharma & Healthcare
- Divi's Laboratories
Divi's Laboratories share price
NSE: DIVISLABPharma & HealthcareDrug Manufacturers - Specialty & Generic
Divi's Laboratories at a glance
Divi's Laboratories (NSE: DIVISLAB) closed at ₹9,141.00 on 22 Oct 2026, up 0.46% on the day. With a market capitalisation of ₹2,43,222 Cr, it ranks 34th by market cap among the 4,183 NSE companies Pivot tracks (a large-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 94.6× trailing earnings, against a return on equity of 15.3% in FY26. Over the past year the share price has risen 39.5%. Its 52-week range is ₹5,647.50 (2 Apr 2026) to ₹9,740.00 (24 Sep 2026); the last close is 6.1% below the high. Promoters held 51.88% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹2,43,222 CrRank 34 on NSE
- P/E (trailing)
- 94.6×
- Price to book
- 9.4×FY26
- ROE
- 15.3%FY26
- ROCE
- 19.4%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 24.3%FY26
- Book value / share
- ₹632.49FY26
- 52-week high
- ₹9,740.0024 Sep 2026
- 52-week low
- ₹5,647.502 Apr 2026
- 1-year return
- +39.5%
- RSI (14-day)
- 47.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.46% | +1.7% | −3.0% | +23.7% | +39.5% |
Divi's Laboratories financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹6,969 Cr | ₹8,960 Cr | ₹7,768 Cr | ₹7,845 Cr | ₹9,360 Cr | — |
| Operating profit | ₹2,666 Cr | ₹3,684 Cr | ₹2,369 Cr | ₹2,163 Cr | ₹2,916 Cr | — |
| Net profit | ₹1,984 Cr | ₹2,960 Cr | ₹1,823 Cr | ₹1,600 Cr | ₹2,191 Cr | — |
| EPS (₹) | ₹75.00 | ₹112.00 | ₹69.00 | ₹60.00 | ₹83.00 | — |
| Cash from operations | ₹1,947 Cr | ₹1,912 Cr | ₹2,460 Cr | ₹1,261 Cr | ₹1,653 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹9,295 Cr | ₹11,728 Cr | ₹12,767 Cr | ₹13,571 Cr | ₹14,969 Cr | ₹16,761 Cr |
Divi's Laboratories shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 51.89% | 51.89% | 51.89% | 51.88% | 51.88% | 51.88% |
| Foreign institutions | 18.01% | 19.74% | 19.39% | 20.08% | 20.29% | 20.20% |
| Domestic institutions | 20.71% | 19.05% | 19.76% | 19.28% | 19.22% | 19.38% |
| Non-institutions | 9.39% | 9.32% | 8.96% | 8.76% | 8.60% | 8.54% |
Divi's Laboratories vs peers
The listed Pharma & Healthcare companies nearest to Divi's Laboratories by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | ₹1,744.40 | +0.33% | +5.6% | ₹4,21,803 Cr | 36.5 | 13.7% |
| DIVISLABDivi's Laboratories | ₹9,141.00 | +0.46% | +39.5% | ₹2,43,222 Cr | 94.6 | 15.3% |
| TORNTPHARMTorrent Pharmaceuticals | ₹4,604.50 | +1.31% | +30.9% | ₹1,75,551 Cr | 72.1 | 25.8% |
| ZYDUSLIFEZydus Lifesciences | ₹1,123.00 | +0.75% | +14.8% | ₹1,13,217 Cr | 22.4 | 18.6% |
| APOLLOHOSPApollo Hospitals Enterprise | ₹7,569.50 | −0.41% | −2.4% | ₹1,09,341 Cr | 56 | 20.5% |
| LAURUSLABSLaurus Labs | ₹2,010.10 | +0.02% | +129.8% | ₹1,08,185 Cr | 121.7 | 8.0% |
| CIPLACipla | ₹1,312.60 | +0.08% | −15.2% | ₹1,07,516 Cr | 27.3 | 11.3% |
Ask anything about Divi's Laboratories
Pivot answers on the live chart with evidence you can check, and tests strategies against DIVISLAB's own history. Try: “Why has DIVISLAB moved over the last three months?” · “Backtest a 50-day moving-average crossover on DIVISLAB over five years” · “Compare DIVISLAB with SUNPHARMA on margins and valuation”
Frequently asked questions about Divi's Laboratories
What is the share price of Divi's Laboratories today?
Divi's Laboratories (NSE: DIVISLAB) last closed at ₹9,141.00 on 22 Oct 2026. Its 52-week high is ₹9,740.00 and its 52-week low is ₹5,647.50.
What is the market cap of Divi's Laboratories?
Divi's Laboratories' market capitalisation is ₹2,43,222 Cr (₹2.43 lakh Cr) at the 22 Oct 2026 close, ranking 34th among the NSE companies Pivot tracks.
What is the P/E ratio of Divi's Laboratories?
Divi's Laboratories trades at a trailing P/E of 94.6. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 56.
What is the ROE and ROCE of Divi's Laboratories?
Return on equity was 15.3% in FY26 and return on capital employed was 19.4% in FY26 (consolidated figures).
Is Divi's Laboratories a debt-free company?
Divi's Laboratories is close to debt-free: its debt-to-equity ratio was 0 in FY26.
How has Divi's Laboratories stock performed over the last year?
Divi's Laboratories' share price has risen 39.5% over the past year, +23.7% over three months and −3.0% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Divi's Laboratories?
As of 30 Jun 2026: promoters 51.88%, foreign institutions 20.20%, domestic institutions 19.38%, non-institutions 8.54%.
Who are Divi's Laboratories' competitors?
The listed Pharma & Healthcare companies closest to Divi's Laboratories by market cap are Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Zydus Lifesciences, Apollo Hospitals Enterprise, Laurus Labs and Cipla.
Is Divi's Laboratories a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Divi's Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DIVISLAB against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with D · all NSE stocks · this page as text